PL3536703T3 - Konsensusowe antygeny gruczołu krokowego, kodujące je cząsteczki kwasu nukleinowego i ich zastosowania - Google Patents

Konsensusowe antygeny gruczołu krokowego, kodujące je cząsteczki kwasu nukleinowego i ich zastosowania

Info

Publication number
PL3536703T3
PL3536703T3 PL19150850T PL19150850T PL3536703T3 PL 3536703 T3 PL3536703 T3 PL 3536703T3 PL 19150850 T PL19150850 T PL 19150850T PL 19150850 T PL19150850 T PL 19150850T PL 3536703 T3 PL3536703 T3 PL 3536703T3
Authority
PL
Poland
Prior art keywords
steatic
molles
consensus
coding
applications
Prior art date
Application number
PL19150850T
Other languages
English (en)
Inventor
David B. Weiner
Jian Yan
Bernadette Ferraro
Niranjan Y. Sardesai
Mathura P. Ramanathan
Original Assignee
The Trustees Of The University Of Pennsylvania
Inovio Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania, Inovio Pharmaceuticals, Inc. filed Critical The Trustees Of The University Of Pennsylvania
Publication of PL3536703T3 publication Critical patent/PL3536703T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y116/00—Oxidoreductases oxidizing metal ions (1.16)
    • C12Y116/01—Oxidoreductases oxidizing metal ions (1.16) with NAD+ or NADP+ as acceptor (1.16.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21077—Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19150850T 2010-11-12 2011-11-14 Konsensusowe antygeny gruczołu krokowego, kodujące je cząsteczki kwasu nukleinowego i ich zastosowania PL3536703T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41317610P 2010-11-12 2010-11-12
US41781710P 2010-11-29 2010-11-29
EP19150850.6A EP3536703B1 (en) 2010-11-12 2011-11-14 Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof
PCT/US2011/060592 WO2012065164A2 (en) 2010-11-12 2011-11-14 Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
EP11839215.8A EP2638055B1 (en) 2010-11-12 2011-11-14 Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same

Publications (1)

Publication Number Publication Date
PL3536703T3 true PL3536703T3 (pl) 2021-10-25

Family

ID=46051609

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19150850T PL3536703T3 (pl) 2010-11-12 2011-11-14 Konsensusowe antygeny gruczołu krokowego, kodujące je cząsteczki kwasu nukleinowego i ich zastosowania

Country Status (16)

Country Link
US (6) US8927692B2 (pl)
EP (3) EP3909973A3 (pl)
JP (6) JP6077450B2 (pl)
KR (5) KR102011026B1 (pl)
CN (2) CN103314002B (pl)
AU (1) AU2011325893B2 (pl)
BR (1) BR112013011705B1 (pl)
CA (1) CA2817709C (pl)
DK (1) DK2638055T3 (pl)
EA (1) EA027315B1 (pl)
ES (1) ES2718846T3 (pl)
MX (3) MX358725B (pl)
PL (1) PL3536703T3 (pl)
SI (1) SI3536703T1 (pl)
WO (1) WO2012065164A2 (pl)
ZA (1) ZA201303390B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
WO2012065164A2 (en) 2010-11-12 2012-05-18 The Trustees Of The University Of Pennsylvania Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
NZ701324A (en) * 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
MX364732B (es) 2012-12-13 2019-05-06 Univ Pennsylvania Vacuna contra el tumor de wilms 1.
EP2931318A4 (en) * 2012-12-13 2016-07-20 Univ Pennsylvania DNA ANTIBODY CONSTRUCTS AND METHODS FOR USE THEREOF
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX369709B (es) * 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
MY196581A (en) * 2013-11-01 2023-04-19 Pfizer Vectors for Expression of Prostate-Associated Antigens
DK3134131T3 (en) 2014-04-23 2022-02-07 Modernatx Inc Nucleic acid vaccines
CA2969214A1 (en) 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
US12150980B2 (en) 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs
KR20230012070A (ko) * 2016-03-21 2023-01-25 데이비드 비. 웨이너 Dna 항체 작제물 및 이의 사용 방법
US20190125852A1 (en) * 2016-06-03 2019-05-02 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
CN106119231A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种肿瘤抗原psa的ctl识别表位肽及其应用
CN106581668B (zh) * 2016-12-31 2020-03-24 广州姿生生物科技有限公司 一种抗原表位肽组合物及其应用
BR112020011443A2 (pt) * 2017-12-13 2020-12-01 Inovio Pharmaceuticals, Inc. molécula de ácido nucleico e seu uso, vetor e seu uso, composição, proteína e vacina
CN111308327B (zh) * 2019-12-02 2021-01-26 电子科技大学 模拟电路故障定位与故障元件参数辨识方法
US20250269010A1 (en) * 2021-02-05 2025-08-28 St Pharm Co., Ltd. Novel nucleic acid molecule

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
NL9020389A (nl) 1989-03-08 1991-12-02 Health Research Inc Systeem voor het in de gastheer selecteren van recombinant-pokkenvirussen.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
ES2090129T3 (es) 1989-03-31 1996-10-16 Univ Washington Vacunas que contienen microorganismos tipo phop avirulentos.
DE69016956T2 (de) 1989-12-04 1995-07-20 Akzo Nobel Nv Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
WO1994009820A1 (en) * 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
DE69434469T2 (de) 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
US5864027A (en) 1993-06-07 1999-01-26 Genentech, Inc. HIV envelope polypeptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6630305B1 (en) * 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CN1198665C (zh) 1997-04-03 2005-04-27 依莱克脱罗弗克脱联合股份有限公司 将药物和核酸导入骨骼肌的方法
JP2002507985A (ja) 1997-06-30 2002-03-12 ローヌ−プーラン・ロレ・エス・アー 横紋筋に核酸を導入する改良法およびその組合せ
DE69941187D1 (de) * 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
US6833438B1 (en) * 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
CA2337652C (en) 1998-07-13 2013-03-26 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6136703A (en) 1998-09-03 2000-10-24 Micron Technology, Inc. Methods for forming phosphorus- and/or boron-containing silica layers on substrates
PL202399B1 (pl) 1998-10-05 2009-06-30 Pharmexa As Zastosowanie adiuwanta i pierwszego analogu polipeptydowego antygenu związanego z komórką lub co najmniej jednego fragmentu kwasu nukleinowego kodującego epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką lub niepatogennego mikroorganizmu lub wirusa, który niesie fragment kwasu nukleinowego, który koduje i wyraża co najmniej jeden epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką, sposób selekcji immunogennego analogu antygenu polipeptydowego związanego z komórką, sposób wytwarzania komórki wytwarzającej analog an
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
AU7994200A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
EP1578371A4 (en) 2002-08-19 2009-05-20 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
US20040175727A1 (en) 2002-11-04 2004-09-09 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
DK2364769T3 (en) 2003-05-30 2016-04-11 Vgxi Inc Apparatus and methods for biomaterialeproduktion
WO2005014780A2 (en) 2003-05-30 2005-02-17 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
EP2163260B1 (en) 2004-01-23 2017-03-15 MSD Italia S.r.l. Chimpanzee adenovirus vaccine carriers
CN100549021C (zh) * 2004-05-27 2009-10-14 森托科尔公司 猕猴前列腺特异性抗原
KR100647847B1 (ko) * 2005-05-27 2006-11-23 크레아젠 주식회사 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법
CA2612225A1 (en) * 2005-06-21 2007-01-04 Cyto Pulse Sciences, Inc. Methods and compositions relating to a vaccine against prostate cancer
EP1951865A4 (en) 2005-11-21 2010-06-23 Sanofi Pasteur Ltd STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES
MX2009003938A (es) 2006-10-27 2009-04-24 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
KR101589511B1 (ko) * 2008-04-04 2016-02-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 치쿤구니야 바이러스 단백질의 공통 서열, 이를 인코딩하는 핵산 분자, 조성물 및 이를 이용하는 방법
PL2326350T3 (pl) * 2008-09-08 2014-03-31 Psma Dev Company L L C Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
WO2010050939A1 (en) * 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
AU2009313714B2 (en) * 2008-11-17 2016-05-19 Inovio Pharmaceuticals, Inc. Antigens that elicit immune response against flavivirus and methods of using same
WO2012065164A2 (en) * 2010-11-12 2012-05-18 The Trustees Of The University Of Pennsylvania Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
US10206997B2 (en) * 2011-11-10 2019-02-19 Bin Wang Facilitator-DNA combination vaccine
JP7781511B2 (ja) * 2016-09-30 2025-12-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｔｅｒｔ免疫原性組成物及びそれを用いた治療方法

Also Published As

Publication number Publication date
EP3536703A1 (en) 2019-09-11
US8927692B2 (en) 2015-01-06
EP3909973A2 (en) 2021-11-17
JP2014500724A (ja) 2014-01-16
KR102131276B1 (ko) 2020-07-08
US20250101399A1 (en) 2025-03-27
JP2018030881A (ja) 2018-03-01
US20130302361A1 (en) 2013-11-14
KR20140004098A (ko) 2014-01-10
KR102364214B1 (ko) 2022-02-17
CN103314002B (zh) 2016-09-07
EA201390689A1 (ru) 2013-11-29
JP6310952B2 (ja) 2018-04-11
EP2638055A2 (en) 2013-09-18
JP2021045171A (ja) 2021-03-25
JP6077450B2 (ja) 2017-02-08
US11980659B2 (en) 2024-05-14
SI3536703T1 (sl) 2022-04-29
KR102011026B1 (ko) 2019-08-14
US20190046621A1 (en) 2019-02-14
US9913885B2 (en) 2018-03-13
WO2012065164A3 (en) 2012-07-26
AU2011325893A1 (en) 2013-05-30
EP3909973A3 (en) 2022-01-26
KR20220025242A (ko) 2022-03-03
MX358725B (es) 2018-09-03
BR112013011705A2 (pt) 2018-03-13
ES2718846T3 (es) 2019-07-04
JP2020108396A (ja) 2020-07-16
EA027315B1 (ru) 2017-07-31
JP2016093199A (ja) 2016-05-26
CN106434676A (zh) 2017-02-22
JP7572152B2 (ja) 2024-10-23
US20150150957A1 (en) 2015-06-04
CA2817709A1 (en) 2012-05-18
KR20190096447A (ko) 2019-08-19
JP7142427B2 (ja) 2022-09-27
JP2023171837A (ja) 2023-12-05
EP2638055A4 (en) 2015-12-30
MX2013005195A (es) 2013-08-27
US20160361403A1 (en) 2016-12-15
MX346784B (es) 2017-03-31
BR112013011705B1 (pt) 2022-04-05
DK2638055T3 (en) 2019-04-23
US20220016228A1 (en) 2022-01-20
ZA201303390B (en) 2016-02-24
US11045535B2 (en) 2021-06-29
EP2638055B1 (en) 2019-01-09
EP3536703B1 (en) 2021-05-26
KR102557275B1 (ko) 2023-07-19
CN103314002A (zh) 2013-09-18
WO2012065164A2 (en) 2012-05-18
CA2817709C (en) 2021-06-01
KR101939150B1 (ko) 2019-01-17
KR20170141811A (ko) 2017-12-26
CN106434676B (zh) 2020-10-23
MX421208B (es) 2025-02-10
KR20200084067A (ko) 2020-07-09
AU2011325893B2 (en) 2016-01-14
MX2018010616A (es) 2022-08-24
US9399056B2 (en) 2016-07-26

Similar Documents

Publication Publication Date Title
PL3536703T3 (pl) Konsensusowe antygeny gruczołu krokowego, kodujące je cząsteczki kwasu nukleinowego i ich zastosowania
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
HUE057004T2 (hu) CD277 elleni antitestek és alkalmazásaik
DK3339323T3 (da) Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
HUE058896T2 (hu) N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
HUE050797T2 (hu) T-sejt módosító vegyületek és alkalmazásaik
DK3662932T3 (da) Anti-cgrp-sammensætninger og anvendelse deraf
EP2553522A4 (en) ELECTROPHORETIC MEDIA
EP3795207C0 (en) NEEDLE-FREE CONNECTOR
DK2768958T3 (da) Kationiske aminlipider og anvendelser deraf
EP2542221A4 (en) CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF
EP2847423A4 (en) ADVANCED GEOTHERMAL SYSTEMS AND METHOD
DK3103478T3 (da) Stabiliserede fibronektin-domænesammensætninger, fremgangsmåder og anvendelser
HRP20150926T4 (hr) Pripravci u krutom stanju
EP2593469A4 (en) MODIFIED POLYPEPTIDES AND PROTEINS AND ITS APPLICATION
EP2649385A4 (en) GEOTHERMIC SYSTEM
IL252154A0 (en) Anti-dr5 antibodies, compositions comprising the same and uses thereof
HUE065900T2 (hu) Módosított relaxin polipeptidek és alkalmazásaik
HUE042531T2 (hu) ASIC1-ellenes antitestek és alkalmazásaik
HUE036183T2 (hu) JC Vírus antitestekre vonatkozó assay
HUE046176T2 (hu) Vesesejt-populációk és alkalmazásaik
BR112013016143A2 (pt) sistema para automação residencial e automação residencial
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES
HUE053623T2 (hu) Vegyületek és azok felhasználása